• In late April 2026, Regeneron Pharmaceuticals reported first-quarter 2026 revenue of US$3,605.4 million and net income of US$727.2 million, affirmed a quarterly dividend of US$0.94 per share for payment on June 4, 2026, completed a prior US$2.31 billion buyback, and authorized a new share repurchase program of up to US$3.00 billion.
• Regeneron also secured U.S. FDA approvals expanding Dupixent to children aged 2 to 11 with chronic spontaneous urticaria and granted accelerated approval for Otarmeni, a free in vivo gene therapy for ultra-rare OTOF‑related hearing loss, underscoring its push into both broader immunology markets and pioneering genetic medicine.
• Next, we’ll examine how the Otarmeni gene therapy approval and related pipeline momentum may influence Regeneron’s existing investment narrative.

The latest GPUs need a type of rare earth metal called Terbium and there are only 30 companies in the world exploring or producing it. Find the list for free.

Regeneron Pharmaceuticals Investment Narrative Recap

To own Regeneron today, you generally need to believe its core franchises, especially Dupixent and Eylea, can support disciplined R&D spending while newer platforms in oncology and genetic medicine gradually matter more. The latest quarter showed higher revenue but lower net income year on year, and the most immediate swing factor still looks like competition and pricing pressure on Eylea, rather than the Otarmeni launch, which is unlikely to move near term earnings in a big way.

The announcement that Regeneron is authorizing a new US$3.00 billion share repurchase program, after completing a prior US$2.31 billion buyback, is the piece of news that ties most directly into the current catalyst debate. For investors watching the impact of Eylea headwinds and elevated R&D on per share results, this renewed buyback authority sits alongside the dividend as an important tool that can influence how much of the company’s pipeline progress ultimately shows up on a per share basis.

Yet, against those positives, the risk that Eylea’s competitive and pricing pressures could weigh more heavily on future revenue than many investors expect is something shareholders should be very aware of...

Regeneron Pharmaceuticals' narrative projects $19.5 billion revenue and $6.1 billion earnings by 2029. This requires 9.4% yearly revenue growth and about a $1.7 billion earnings increase from $4.4 billion today.

Uncover how Regeneron Pharmaceuticals' forecasts yield a $875.31 fair value, a 25% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts, who were once modeling revenue near US$21.0 billion and earnings around US$7.4 billion by 2029, see Dupixent’s broad Type 2 inflammation opportunity very differently from those focused on Eylea’s headwinds, and the latest approvals and capital return moves could eventually shift which of those stories feels closer to reality.

Explore 9 other fair value estimates on Regeneron Pharmaceuticals - why the stock might be worth 6% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Regeneron Pharmaceuticals research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Regeneron Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Regeneron Pharmaceuticals' overall financial health at a glance.

Want Some Alternatives?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.